Wenbo Meng is an expert in Gastroenterology at First Hospital of Lanzhou University (China). As of October 2026, ScienceLeadR ranks Wenbo Meng in the top 1% of experts worldwide for Gallbladder Diseases, Biliary Tract Diseases and Bile Duct Diseases. Wenbo Meng has authored 202 publications, the most recent in 2026, and is an investigator in 22 clinical trials, 6 of them ongoing. SLR score: 1,317 (community average: 125). How the SLR is computed.

LeadR Profile

1 317 ScienceLeadR Reputation 1317
Network Map

Gastroenterology

Subspecialties: Oncology - Biochemistry - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2013 - 2026
Source: PubMed

First Hospital of Lanzhou University

2013 - 2026

Lanzhou University

2016 - 2026

Lanzhou University Second Hospital

2023 - 2026

Publications Synthesis

Sources: PubMed, OpenAlex

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Integrated Bile Metabolomics and Serum Biomarkers for Differentiating Cholangiocarcinoma from Cholelithiasis.
PMID 42940162 — pyruvic acid, bile, serum, biomarkers, cholelithiasis, metabolomics, tyrosine, cholangiocarcinoma
Biomedicines20260
Multi-Omics and Molecular Simulation Identify KIF11 as a Candidate Direct Target of Resveratrol in Hepatocellular Carcinoma.
PMID 42670538 — cells, genes, carcinoma, hepatocellular, multiple chronic conditions, biomarkers, immunotherapy, therapeutics, molecular dynamics simulation, resveratrol, prognosis
J Hepatocell Carcinoma20260
Effect of preoperative body composition on long-term outcomes in patients undergoing distal cholangiocarcinoma resection.
PMID 42613374 — muscles, subcutaneous fat, body composition, subcutaneous tissue, obesity, muscle, skeletal, tissues, prognosis, cholangiocarcinoma, sarcopenia, extrahepatic cholangiocarcinoma
Sci Rep20260
Functional fatty acid-based dietary therapy as a new strategy for small gallstone expulsion: study protocol for a prospective, single-center, double-blind, randomized controlled trial.
PMID 42490892 — gallstones, gallbladder, signs and symptoms, cholelithiasis, therapeutics, fatty acids
Front Nutr20260
Leaving No Stone Unturned - Update on the Current Approach to Diagnosing and Treatment of Idiopathic Acute Pancreatitis.
PMID 42420697 — gastroenterology, pancreatitis, therapeutics
Dig Dis Sci20260

Clinical Studies 22

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4

By phase:

N/A 21
Phase 3 1

By status:

Completed 15
Recruiting 4
Not yet recruiting 2
Unknown 1

By type:

Interventional 15
Observational 7

By Monocentric/Multicentric:

monocentric 12
multicentric2to4 3
multicentric5to9 2
multicentricup10 5

Main Topics

Ongoing Clinical Trials

6 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Bao Yuan Tang Extract and Galactooligosaccharides for Sleep Regulation
NCT07774897 — endocrine system, sleep, fatigue syndrome, chronic, health status, lipid metabolism disorders, maintenance, prebiotics, fatigue, parasomnias, sleep initiation and maintenance disorders, glucose metabolism disorders, endocrine system diseases, lipids
N/ANot yet recruiting2026
The Optimal Measurement Time for the New Gallbladder Function Assessment Method
NCT07321431 — research design, administration, oral, eggs, gallbladder, olive oil
N/ARecruiting2026
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
NCT07165951 — injections, growth, transforming growth factors, paclitaxel, pharmaceutical preparations, transforming growth factor beta, adenocarcinoma, drug therapy, capsules, therapeutics, chemotherapy
Phase 3Recruiting2025
Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer
NCT07091526 — pancreatic neoplasms, uric acid, blood, serum, pancreaticoduodenectomy, neoplasms, pancreatectomy
N/ARecruiting2025
A Strategy for Gallstone Expulsion Through Dietary Therapy
NCT06699030 — administration, oral, gallstones, cholecystitis, gallbladder, cholecystolithiasis, therapeutics, fatty acids
N/ARecruiting2024

LeadR Networks

Main global connection map